Skip to main content

Table 3 Eligibility criteria for the proximal humerus fracture group

From: Does osteoporosis increase complication risk in surgical fracture treatment? A protocol combining new endpoints for two prospective multicentre open cohort studies

Inclusion criteria (proximal humerus)
   • Radiologically confirmed closed fracture (≤ 10 days) of the proximal humerus
   • All dislocated (according to modified Neer*) proximal humerus fractures except dislocated fractures of the greater and lesser tuberosity
   • Primary fracture treatment with a PHILOS plate
   • Age ≥ 50 and ≤ 90 years
   • Normal (pre-trauma) function of both shoulders according to age
   • Monotrauma
   • Willing and able to give written informed consent to participate in the study
   • Willing and able to participate in the study follow-ups according to the study protocol
   • Willing and able to comply with the postoperative management program
   • Able to understand and read country national language at an elementary level
Exclusion criteria (proximal humerus)
   • Open proximal humerus fracture
   • Concomitant contralateral proximal humerus fracture
   • Previous proximal humerus fracture on either side after the age of 25
   • Time to operation > 10 days
   • Polytrauma
   • Cuff arthropathy of the contralateral proximal humerus
   • Associated nerve or vessel injury
   • Regular systemic therapy with corticosteroids due to chronic disease
   • Legal incompetence
   • Patient received radio- or chemotherapy prior to, during or within the last year
   • Currently diagnosed with active cancer
   • Recent history of substance abuse (i.e. recreational drugs, alcohol)
   • Prisoner
   • Currently involved in a pharmaceutical clinical study**
   • Has a disease process that would preclude accurate evaluation (e.g. neuromuscular or rheumatic disease, significant psychiatric or metabolic disorders)
  1. * Segment displacement > 0.5 cm or angulated > 45° [15].
  2. ** Simultaneous participation in another orthopaedic/surgical study with the same or another fracture will be approved by the principal clinical investigator